Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mono Clear all
Suspended Phase 1Phase 2 Interventional

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

NCT05138458
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
Interventions
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Biological · Other
Lead sponsor
Myeloid Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

NCT05763875
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Postprandial Monocyte Study

NCT05792137
View directory record Official record
Conditions
Immune System, Nutrition, Inflammation
Interventions
High saturated fat challenge meal, High mono unsaturated fat challenge meal
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 39 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluate the Continued Safety and Performance of the Foot and Ankle Products

NCT04715139
View directory record Official record
Conditions
Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle, Lisfranc Arthrodesis, Mono or Bi-cortical Osteotomies in the Forefoot, First Metatarsophalangeal Arthrodesis, Akin Osteotomy, Midfoot and Hindfoot Arthrodeses or Osteotomies, Fixation of Osteotomies for Hallux Valgus Treatment (Scarf and Chevron), Arthrodesis of the Metatarsocuneiform Joint to Reposition and Stabilize Metatarsus Primus Varus, Osteotomy Fixation of Hallux Valgus Repair (Such as Scarf and Chevron Etc.), Medial Ankle Stabilization, Tibiotalocalcaneal Arthrodesis
Interventions
Products listed in Group/Cohort Description
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
2 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 24, 2026, 5:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents

NCT06007404
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance, Obesity, Metabolic Disease, PreDiabetes
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 18 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

NCT01052701
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Ribavirin, Ribavirin plus Abacavir (ABC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 24, 2026, 5:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers

NCT00027482
View directory record Official record
Conditions
Healthy, HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

NCT00485550
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mono-menotropins Versus rFSH Protocol on Embryo Quality

NCT02418533
View directory record Official record
Conditions
Infertility, Fertility
Interventions
menotropin, Recominant Follicle Stimulating Hormone (rFSH)
Drug
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 38 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

NCT00001112
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Interferon gamma-1b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Results available

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

NCT01263938
View directory record Official record
Conditions
HIV Dementia
Interventions
Atorvastatin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 24, 2026, 5:06 AM EDT
Completed No phase listed Observational

Monocytosis and Culprit Vessel in STEMI Patients

NCT01569646
View directory record Official record
Conditions
STEMI
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

NCT02435277
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Mid Metformin, High Metformin, Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

NCT00324506
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (CellCept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

NCT00000886
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 C4-V3 Polyvalent Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
3
States / cities
Rochester, New York • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

NCT01290055
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water
Biological · Other
Lead sponsor
Sri Edupuganti
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Completed No phase listed Observational

Reasons for Non-treatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting

NCT00222859
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

NCT05483907
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BBT-877, Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Completed No phase listed Observational

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

NCT00232193
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
Providence Multiple Sclerosis Center
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Effects of Diet Interventions on Monocytes in Metabolic Syndrome

NCT03591588
View directory record Official record
Conditions
Metabolic Syndrome, Hypertriglyceridemia
Interventions
diet
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

NCT03068351
View directory record Official record
Conditions
Multiple Myeloma
Interventions
RO6870810, daratumumab
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Duarte, California • Stanford, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 24, 2026, 5:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Blood Test to Look at Cells of the Immune System in Healthy Children

NCT00001109
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 18 Years
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Novel Dietary Interventions for Treating Insulin Resistance

NCT02006394
View directory record Official record
Conditions
Insulin Resistance, Obesity, Metabolic Syndrome
Interventions
Fish Oil, Polyphenol Capsules, Corn Oil Capsules, Corn starch capsules, Reduced glycemic index bread products, Market variety bread products
Dietary Supplement · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 24, 2026, 5:06 AM EDT